Ovid Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

Ovid Therapeutics (NASDAQ: OVID), a biopharmaceutical company focused on epilepsy treatments, will present at the 22nd Annual Needham Virtual Healthcare Conference on April 17, 2023, at 11:00 a.m. ET. Management aims to highlight their innovative therapies and ongoing research.

An archived replay of the presentation will be available on their website post-event. Ovid's pipeline includes OV329, a GABA-aminotransferase inhibitor for treatment-resistant seizures, and OV350, targeting epilepsies. Additionally, Ovid is significantly involved in the soticlestat development, currently in Phase 3 trials for Dravet and Lennox-Gastaut syndromes, managed by Takeda. For further information about Ovid's initiatives, visit ovidrx.com.

NEW YORK, April 10, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a  biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders, today announced that management will present at the 22^nd Annual Needham Virtual Healthcare Conference on April 17, 2023 at 11:00 a.m. ET.

A live webcast of the presentation can be accessed through the Events & Presentations section of the Company’s website at investors.ovidrx.com. An archived replay of the webcast will be available on the Company’s website following the live presentation.

About Ovid Therapeutics
Ovid Therapeutics Inc. is a New York-based biopharmaceutical company striving to conquer seizures and brain disorders with courageous science. Ovid’s pipeline of small molecule and genetic medicines candidates seek to meaningfully improve the lives of people and families affected by epilepsies and seizure-related disorders. Ovid is developing OV329, a GABA-aminotransferase inhibitor, for the potential treatment of treatment-resistant seizures, and OV350, a direct activator of the KCC2 transporter, for potential treatment of epilepsies. In addition, Ovid maintains a significant financial interest in the future regulatory development and potential commercialization of soticlestat, which Takeda is responsible for advancing globally. Soticlestat is a cholesterol 24-hydroxylase inhibitor, which is currently in Phase 3 trials for Dravet and Lennox-Gastaut syndromes. For more information about these and other Ovid research programs, please visit www.ovidrx.com.

Forward-Looking Statements
This press release includes certain disclosures that contain “forward-looking statements,” including, without limitation: the potential development and use of OV329, OV350 and the status of Takeda’s two pivotal Phase 3 trials evaluating soticlestat for Lennox-Gastaut and Dravet syndromes. You can identify forward-looking statements because they contain words such as “anticipates,” “believes,” “expected,” “intends,” “plan,” “potential,” and “will,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Forward-looking statements are based on Ovid’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, uncertainties inherent in the preclinical and clinical development and regulatory approval processes, the risk that Ovid may not be able to realize the intended benefits of its technology. Additional risks that could cause actual results to differ materially from those in the forward-looking statements are set forth under the caption “Risk Factors” in Ovid’s Quarterly Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 13, 2023, and in future filings Ovid makes with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Ovid assumes no obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

Contacts
Investors and Media:
Ovid Therapeutics Inc.
Meg Alexander
917-943-6681
malexander@ovidrx.com

OR

Investors:
Argot Partners
Maeve Conneighton
212-596-7231
ovid@argotpartners.com

FAQ

What is Ovid Therapeutics presenting at the Needham Virtual Healthcare Conference?

Ovid Therapeutics will present their advancements in epilepsy treatments at the 22nd Annual Needham Virtual Healthcare Conference on April 17, 2023.

When is Ovid Therapeutics' presentation at the Healthcare Conference?

The presentation is scheduled for April 17, 2023, at 11:00 a.m. ET.

How can I access the Ovid Therapeutics conference presentation?

A live webcast and an archived replay of the presentation can be accessed on Ovid Therapeutics' website at investors.ovidrx.com.

What are the key products Ovid Therapeutics is developing?

Ovid is developing OV329 and OV350 for seizure disorders, and has a financial interest in soticlestat, which is in Phase 3 trials.

What is the status of soticlestat in development by Ovid Therapeutics?

Soticlestat is currently in Phase 3 trials for Dravet and Lennox-Gastaut syndromes, with Takeda responsible for its development.